Biotech for less than cash value Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech for less than cash value

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: RWReeves who started this subject	10/15/2002 7:14:40 AM
From: nigel bates	of 684

INMX munched - Message 18113741 Other candidates ? nig (edit) nil premium, though InforMax also announced today that it is revising its guidance for the fourth quarter of 2002. The Company currently expects revenue for the quarter in the range of $4.5 million to $5.0 million. It is anticipated that the benefits of the Company's continued cost reduction measures will result in an adjusted net loss per share in the range of $0.15 to $0.17, excluding non-cash charges. InforMax also retains its strong balance sheet with over $47.0 million in cash and investments in government securities and commercial paper, and the Company estimates a cash position of approximately $41.0 million by year-end 2002, which is approximately $2.0 million more favorable than previous estimates...

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next